NRXS (Neuraxis) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Effect of Exchange Rate Changes?

Neuraxis's Effect of Exchange Rate Changes for the three months ended in Mar. 2025 was $0.00 Mil.

Neuraxis's Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.

Neuraxis Effect of Exchange Rate Changes Historical Data

The historical data trend for Neuraxis's Effect of Exchange Rate Changes can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Effect of Exchange Rate Changes Chart

Neuraxis Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Effect of Exchange Rate Changes

Neuraxis Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Effect of Exchange Rate Changes	Get a 7-Day Free Trial										-	-	-	-	-

Neuraxis Effect of Exchange Rate Changes Calculation

Effect of Exchange Rate Changes represents the effect of exchange rate changes on cash balances held in foreign currencies.

Effect of Exchange Rate Changes for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Neuraxis Effect of Exchange Rate Changes Related Terms

Thank you for viewing the detailed overview of Neuraxis's Effect of Exchange Rate Changes provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuraxis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Effect of Exchange Rate Changes

Comparable Companies

Traded in Other Exchanges

N/A

Address

11611 N. Meridian Street, Suite 330, Carmel, IN, USA, 46032

Website

http://www.neuraxis.com

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Executives

Masimo Corp	10 percent owner	52 DISCOVERY, IRVINE CA 92618
John G Seale	officer: CHIEF FINANCIAL OFFICER	10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico	director, officer: CEO, DIRECTOR	11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown	director, officer: DIRECTOR OF INNOVATION	829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence	officer: CHIEF OPERATING OFFICER	10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico	officer: CHIEF REGULATORY OFFICER	829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson	officer: DIR.OF DESIGN & ENGINEERING	829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins	director	10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser	director	220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs	director	324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda	officer: Chief Medical Officer, SVP	829 S. ADAMS STREET, VERSAILLES IN 47042